https://www.thebodypro.com/category/hiv-treatment-as-prevention/tag/news

The Latest

doctor patient hands

This Week in HIV Research: Health in Unity

Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.

By Barbara Jungwirth and Myles Helfand
intimate

Understanding U=U Can Improve Health Outcomes for People Living with HIV—but the Message Matters

W. David Hardy, M.D., discusses the takeaway messages for HIV care providers after a recent research paper found that a third of all people living with HIV reported never discussing U=U with their provider.

By Terri Wilder, M.S.W.
COVID-19 mask profile

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
MSM

This Week in HIV Research: Incidence and Clinical Care Trends Among MSM

Oct. 1, 2020: HIV surveillance trends among U.S. MSM; health insurance and viral suppression; PrEP prescribing among motivated clinicians; PrEP sharing between MSM.

By Barbara Jungwirth and Myles Helfand
Juan Berenguer, M.D., Ph.D. and Antonio Urbina, M.D.

Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM

Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.

By Terri Wilder, M.S.W. and Myles Helfand
brain dissipation

This Week in HIV Research: What We Don’t Know Hurts Them

Aug. 20, 2020: HIV knowledge and stigma among health care workers in the southern U.S.; condomless sex vs. HIV risk among MSM; how drug class choice may affect onward transmission risk; STI screening rates among MSM on PrEP.

By Barbara Jungwirth and Myles Helfand
integrase inhibitor

This Week in HIV Research: The Fast-Acting Power of Integrase

April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.

By Barbara Jungwirth and Myles Helfand
virology

This Week in HIV Research: Is Viral Suppression an STI Prevention Tool?

March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.

By Barbara Jungwirth and Myles Helfand
men on beach

This Week in HIV Research: Do You Believe in U=U?

Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.

By Barbara Jungwirth and Myles Helfand
three human skeleton models doing "see no evil, hear no evil, speak no evil"

This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

By Barbara Jungwirth and Myles Helfand